(4aR,8aR)-decahydroquinoline | 10343-99-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉类
• 英文名称: (4aR,8aR)-decahydroquinoline
• 英文别名: cis-4aR,8aR-Decahydroquinoline；cis-decahydroquinoline；DHQ；decahydro-quinoline；Decahydro-chinolin；cis-Decahydrochinolin；(4aR,8aR)-1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline
• CAS: 10343-99-4
• 化学式: C₉H₁₇N
• mdl: MFCD00137756
• 分子量: 139.241
• InChiKey: POTIYWUALSJREP-RKDXNWHRSA-N

物化性质

• 熔点：
  -40°C
• 沸点：
  245.24°C (rough estimate)
• 密度：
  0.9426

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  potassium methyl sulfate 、 (4aR,8aR)-decahydroquinoline 在 水 作用下， 生成 N-methyl-trans-decahydroquinoline
  参考文献：
  名称：

  Bamberger; Williamson, Chemische Berichte, 1894, vol. 27, p. 1470

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(2-氧代-环己基)-丙酸 在 palladium dihydroxide lithium aluminium tetrahydride 、 三氯化铝 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 甲苯 为溶剂， 反应 39.75h， 生成 (4aR,8aR)-decahydroquinoline
  参考文献：
  名称：

  动态动力学拆分和去对称化过程：哌啶的对映选择性合成的直接方法。

  摘要：

  报道了合成对映纯多取代哌啶的简单方法。它涉及直接产生已经在杂环上掺入碳取代基的手性非外消旋恶唑并[3，2-a]哌啶酮内酰胺，随后除去手性助剂。关键步骤是（R）-苯基甘醇或其他氨基醇与外消旋或手性δ-氧代（二）酸衍生物在高度立体选择性的过程中进行的环缩合反应，该过程涉及动态动力学拆分和/或非对映体或对映体酯基的去对称化。

  DOI：

  10.1002/chem.200600420

文献信息

• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BÊTA-HSD1
  申请人：UNIV EDINBURGH

  公开号：WO2009074789A1

  公开（公告）日：2009-06-18

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. Formula (I).

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括2型糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。公式（I）。
• [EN] 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE SUBSTITUES EN POSITION 4
  申请人：BIOAXONE THERAPEUTIQUE INC

  公开号：WO2005080394A1

  公开（公告）日：2005-09-01

  Substituted piperidine compounds represented by the structure I are provided, wherein each of Rla, R1b, R1c, R1d, Rle, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x, and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.

  提供了由结构I表示的取代哌啶化合物，其中Rla、R1b、R1c、R1d、Rle、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n中的每一个如规范中定义。结构I的取代哌啶化合物可能渗透或穿过神经细胞膜进入神经细胞内部，可能抑制哺乳动物神经细胞中的细胞内Rho激酶酶，并可能在这些哺乳动物的中枢和外周神经系统中修复受损神经时发挥作用。这些化合物可能诱导哺乳动物神经细胞中神经突起的再生或生长，从而诱导受损或患病神经组织的再生。这些化合物还可作为Rho激酶酶拮抗剂在治疗涉及Rho激酶的疾病状态中发挥额外作用。含有这些取代哌啶化合物的药物组合物可能有助于促进神经突起的生长，并在需要Rho激酶抑制的疾病治疗中发挥作用。
• Simultaneous hydrodenitrogenation and hydrodesulfurization on unsupported Ni-Mo-W sulfides
  作者：Sylvia Albersberger、Jennifer Hein、Moritz W. Schreiber、Santiago Guerra、Jinyi Han、Oliver Y. Gutiérrez、Johannes A. Lercher

  DOI：10.1016/j.cattod.2017.05.083

  日期：2017.11

  The catalytic properties of unsupported Ni-Mo-W sulfides (composites of Ni-Mo(W)S2 mixed sulfides and Ni3S2) obtained from precursors synthesized via co-precipitation, hydrothermal, and thiosalt decomposition were explored for hydrodenitrogenation (HDN) of o-propylaniline or quinoline in presence and absence of dibenzothiophene undergoing hydrodesulfurization (HDS). The conversion rates varied with

  探索了通过共沉淀，水热和硫盐分解合成的前驱体获得的无载体Ni-Mo-W硫化物（Ni-Mo（W）S 2混合硫化物和Ni 3 S 2的复合物）的催化性能，以进行加氢脱氮（HDN）在存在和不存在二苯并噻吩进行加氢脱硫（HDS）的情况下）的邻丙基苯胺或喹啉。转化率随反应的底物而变化，并与特定的催化剂性能有关，例如形态，质地，表面和组成。为的HDN Ó -propylaniline和二苯并噻吩的存在的HDS Ò-丙基苯胺，高浓度的配位不饱和阳离子位点（以NO吸附为特征）和比表面积决定了反应速率。对于喹啉的HDN和在喹啉的存在下二苯并噻吩的加氢脱硫，硫化钨和板坯的长度的高加氢活性被认为是比在例更重要ö -propylaniline。总体而言，只要镍存在于平板周围，无载体催化剂的活性就与平板的大小有关。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Pharmacyclics, Inc.

  公开号：US20150158865A1

  公开（公告）日：2015-06-11

  Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了布鲁顿酪氨酸激酶（Btk）的可逆和不可逆抑制剂。还披露了包括这些化合物的药物组合物。描述了使用Btk抑制剂的方法，单独或与其他治疗剂联合用于治疗自身免疫疾病或症状、异种免疫疾病或症状、包括淋巴瘤在内的癌症，以及炎症性疾病或症状。
• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION
  申请人：UNIV EDINBURGH

  公开号：WO2009112845A1

  公开（公告）日：2009-09-17

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺-噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）的作用。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物，在体内和体外，抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。

表征谱图